Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

NCT07389590 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Ublituximab
DRUG: Ocrelizumab

Sponsor

Johns Hopkins University

Collaborators

[object Object]